EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Mironid Extends Series A Round Raising £35 Million to Date for Development of First-In-Class Small Molecules to Treat Life-Threatening Hereditary Kidney Disease
Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney
Nyra Medical names Lori Chmura as Chief Executive Officer
ATLANTA, GA – Nyra Medical, an innovative medical device company developing a next generation transcatheter mitral valve repair technology, announced the appointment of Lori Chmura as Chief Executive
NodThera is First To Demonstrate Reduction in Neuroinflammation in the Clinic With Brain Penetrant NLRP3 Inflammasome Inhibitor
– NT-0796 demonstrates reduction of multiple neuroinflammatory and inflammatory biomarkers in plasma and CSF of elderly volunteers in just 7 days – Individuals with the
NodThera Announces Positive First-In-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
BOSTON, MA. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from first-in-human studies
Kynos Therapeutics Announces a First-In-Human Phase I study of its Novel Small Molecule KMO Inhibitor, KNS366, is Underway
EDINBURGH UK – Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is
Apellis Presents Phase 3 Functional Analyses of SYFVORE™ (pegcetacoplan injection) for Geographic Atrophy
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
Edinburgh and Cambridge, UK, – Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered into a worldwide drug discovery collaboration agreement with
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug